Profile: Transition Therapeutics Inc (TTH.TO)

TTH.TO on Toronto Stock Exchange

8.05CAD
29 Aug 2014
Price Change (% chg)

$0.05 (+0.63%)
Prev Close
$8.00
Open
$8.05
Day's High
$8.05
Day's Low
$8.05
Volume
111
Avg. Vol
2,496
52-wk High
$9.25
52-wk Low
$4.04

Search Stocks
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company’s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer’s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer’s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.

Company Address

Transition Therapeutics Inc

SUITE 220, 101 COLLEGE STREET
TORONTO   ON   M5G 1L7
P: +1416.2607770
F: +1416.2602886

Search Stocks